The New Zealand market for Penicillins and Streptomycins in Dosage has seen fluctuating trends over the past decade. From 2013 to 2023, there has been a general decline with a few intermittent years of growth. In 2023, the market stood at 59.707 million USD, representing a slight decline of 1.18% from the previous year. The compound annual growth rate (CAGR) over the last five years was -1.53%, pointing to a modest downward trend. Year-on-year variations exhibit volatility, with noticeable drops in 2022 and a stabilization in 2023.
Future trends to watch for include:
- Potential impact of healthcare policy changes or new regulations.
- Innovation in antibiotic development, which could influence market dynamics.
- Changes in demand due to shifts in treatment protocols and resistance patterns.
- Economic factors that might affect healthcare budgets and spending.
How does New Zealand rank in Penicillins and Streptomycins in Dosage Market Size Value?
| # | 33 Countries | US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 4,303,400,000 | 2023 | +0.61% | +1.48% | View data |
| 2 | 2 United Kingdom | 730,000,000 | 2023 | -1.31% | -1.45% | View data |
| 3 | 3 France | 717,200,000 | 2023 | -1.91% | +0.034% | View data |
| 4 | 4 Italy | 622,330,000 | 2023 | -3.96% | -4.86% | View data |
| 5 | 5 Germany | 476,270,000 | 2023 | +1.03% | +1.1% | View data |
| 17 | 17 Malaysia | 62,268,000 | 2023 | +7.35% | +7.89% | View data |
| 18 | 18 Czech Republic | 60,391,000 | 2023 | -3.18% | -4.46% | View data |
| 19 | 19 New Zealand | 59,707,000 | 2023 | -1.18% | -1.53% | |
| 20 | 20 Portugal | 50,167,000 | 2023 | +0.83% | -0.0056% | View data |
| 21 | 21 Switzerland | 49,944,000 | 2023 | -1.64% | -1.63% | View data |
